Skip to main
IMGN
IMGN logo

ImmunoGen (IMGN) Stock Forecast & Price Target

ImmunoGen (IMGN) Analyst Ratings

Based on 20 analyst ratings
Hold
Strong Buy 20%
Buy 5%
Hold 70%
Sell 5%
Strong Sell 0%

Bulls say

Immunogen is a promising biotechnology company with a strong focus on antibody-drug conjugate (ADC) technology, which has shown great potential in delivering targeted cancer treatments. With a pipeline of three additional ADCs and upcoming ASH data as a key catalyst, Immunogen is poised for success in the near future. While there are risks involved, the company's partnerships and deep pipeline make it a sound investment option for those with a positive outlook.

Bears say

Immunogen is currently rated as Neutral, with a 12-month price target of $31.26 due to its recent cash acquisition by AbbVie. The target price is based on a SOTP analysis with a 6.5% WACC, primarily driven by NPV of mirvetuximab soravtansine cash flows through 2038, and near-term catalysts include Phase 1 updates for IMGC936 and Pivekimab triplet data in December 2023.

ImmunoGen (IMGN) has been analyzed by 20 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 5% recommend Buy, 70% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ImmunoGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ImmunoGen (IMGN) Forecast

Analysts have given ImmunoGen (IMGN) a Hold based on their latest research and market trends.

According to 20 analysts, ImmunoGen (IMGN) has a Hold consensus rating as of Aug 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ImmunoGen (IMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.